Tasman Therapeutics Announces Strategic Partnership with Osmind to Advance R-107 for Depressive Disorders

PartnershipR-107Positive

AI Analysis

Summary

Tasman Therapeutics announced a strategic partnership with Osmind to advance R-107, an oral extended-release ketamine product for depressive disorders, leveraging Osmind's real-world evidence platform to support the Phase 3 ROCKET program and commercialization efforts.

Clinical Trial Data

Phase

Phase 3

Importance:6/10

Sentiment:

0.50

partnershipPhase 3ketaminedepressive disordersreal-world evidencelaunch readiness

Related Companies

$NHPAP $RCKTW $WHEN

Read the original article

Published by PR Newswire Pharma on August 12, 2026 12:00 PM

Read Original